1447723-92-3

Downstream Products

• 1447726-01-3 2-(3,5-bis-(4-fluoro-phenyl)-(1,2,4)triazol-1-yl)-1-(4-(6-dimethylamino-pyrimidin-4-yl)-piperazin-1-yl)-ethanone 
• 1447726-05-7 2-(3,5-bis-(4-fluoro-phenyl)-(1,2,4)triazol-1-yl)-1-(4-(6-(2-hydroxy-ethoxy)-pyrimidin-4-yl)-piperazin-1-yl)-ethanone 
• 1447726-31-9 2-(3,5-bis-(4-fluoro-phenyl)-(1,2,4)triazol-1-yl)-1-(4-(6-(4-methoxy-butoxy)-pyrimidin-4-yl)-piperazin-1-yl)-ethanone 
• 1447726-06-8 2-(3,5-bis-(4-fluoro-phenyl)-(1,2,4)triazol-1-yl)-1-(4-(6-(methyl-(tetrahydro-furan-3-ylmethyl)-amino)-pyrimidin-4-yl)-piperazin-1-yl)-ethanone 

Relevant academic research and scientific papers

SUBSTITUTED TRIAZOLES AND THEIR USE FOR TREATMENT AND/OR PREVENTION NEUROLOGICAL AND PSYCHIATRIC DISORDERS

This invention relates to compounds of formula (I), their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.